VCP Scanner
Stock Screener
Filter stocks with fundamental & technical criteria
Market Themes
Curated industry baskets & thematic leaders
Earnings Hub
Calendar, EPS surprise stats & earnings transcripts
Market News
Real-time market intelligence & AI overviews
Insider Buying
SEC Form 4 corporate insider purchases
LearnAll lessons
Candlestick Patterns44 candles, each on two real charts
Pattern GuidesThe playbooks' setups on real breakouts
GlossaryInvesting terms in plain English
MinerviniVCP SetupsTrend Template
O'NeilCup with HandleFlat BaseDouble BottomCANSLIM Leaders
QullamaggieHigh Tight FlagsFlag BreakoutsEpisodic PivotsMomentum Leaders
KellWedge PopEMA Crossback
LivermorePivotal Points
PatternsFalling Wedge & ChannelBase Breakouts
View All Playbooks...
BreakoutsScanner
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Index & ETFs
SPY vs QQQVTI vs VOOSPY vs IWM
Compare Any Stocks...
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Watchlist
BreakoutsScanner
WatchlistPricing
Ctrl K
Pricing
ZSQR
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Scanner
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsScannerWatchlist
ZSQRZ Squared Inc.
$2.23$178M
Overview & Tools
OverviewChart Terminal ↗Visualize
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice History
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Discovery & Screens
Live BreakoutsStock ScreenerOwnership
  1. Home
  2. Financial Ratios

  1. Home
  2. Stocks
  3. ZSQR
  4. Financial Ratios

Z Squared Inc. (ZSQR) Financial Ratios

Latest Ratios: P/E Ratio -5.0x · EV/EBITDA N/A · ROE -100.5%. (2004–2025 historical series)

Income StatementBalance SheetCash FlowRatios
AnnualQuarterly

ZSQR Valuation Multiples

Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2005FY 2004
Market Cap$110M$60M$11M$20M$22M$109M$96M———
Enterprise Value$105M$55M$11M$20M$20M$111M$95M———
P/E Ratio →-5.03—————————
P/S Ratio39.5044.27———1455.27————
P/B Ratio0.533.401.774.674.9146.431.78———
P/FCF——————————
P/OCF——————————

P/E links to full P/E history page with 30-year chart

ZSQR EV Ratios

Enterprise-value multiples — capital-structure-neutral measures of total business value

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2005FY 2004
EV / Revenue—40.31———1480.64————
EV / EBITDA——————————
EV / EBIT——————————
EV / FCF——————————

ZSQR Profitability

Margins and return-on-capital ratios measuring operating efficiency

Margins

Full margin charts and quarterly trend are on the Earnings History page

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2005FY 2004
Gross Margin-207.8%-207.8%———-496.6%————
Operating Margin-956.9%-956.9%———-18727.9%————
Net Profit Margin-874.3%-874.3%———-17932.4%————

Return on Capital

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2005FY 2004
ROE-100.5%-100.5%-207.8%-485.1%-1104.5%-47.9%-32.1%-14.2%——
ROA-77.3%-77.3%-112.0%-266.1%-511.9%-32.2%-22.5%-1.4%-343.2%5642.7%
ROIC-102.0%-102.0%-138.3%-474.9%-735.8%-36.9%————
ROCE-106.2%-106.2%-173.7%-397.0%-701.9%-34.8%-0.1%———

ZSQR Leverage & Debt

Solvency and debt-coverage ratios — lower is generally safer

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2005FY 2004
Debt / Equity0.020.020.230.280.461.74—9.73——
Debt / EBITDA———————0.89—0.04
Net Debt / Equity—-0.300.15-0.06-0.390.81-0.029.70——
Net Debt / EBITDA———————0.89—0.04
Debt / FCF—————————0.06
Interest Coverage-18.11-18.11-22.53-196.49-171.03-70.87————

Net cash position: cash ($6M) exceeds total debt ($268875)

ZSQR Liquidity & Efficiency

Short-term solvency ratios and asset-utilisation metrics

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2005FY 2004
Current Ratio4.164.160.230.591.810.79191.800.000.220.00
Quick Ratio4.164.160.230.591.810.79191.800.000.220.00
Cash Ratio3.593.590.120.491.750.79181.440.000.220.00
Asset Turnover—0.07———0.01————
Inventory Turnover——————————
Days Sales Outstanding—1.97————————

ZSQR Shareholder Yields

Earnings, FCF, buyback, and dividend yields — total returns to shareholders

Dividends

Full dividend history and growth charts are on the Dividend History page

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2005FY 2004
Dividend Yield——————————
Payout Ratio——————————

Total Shareholder Return Metrics

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2005FY 2004
Earnings Yield——————————
FCF Yield——————————
Buyback Yield0.0%0.0%0.0%0.0%0.0%0.2%0.0%———
Total Shareholder Yield0.0%0.0%0.0%0.0%0.0%0.2%0.0%———
Shares Outstanding—$4M$2M$1M$714783$545728$468750$11M$1863$1863

Key Metrics

Growth RegimeMixed
ProfitabilityNegative
Balance SheetVulnerable
Cash FlowBurning
Top Statement Risk

Imminent liquidity and dilution

Verified Source

Metrics are mathematically derived from official filings.

SEC 10-K (2026Q1)

Speculative Pricing Amidst Clinical Uncertainty

According to recent market data, COEP trades at a price-to-sales ratio of 32.07, which appears to reflect an aggressive valuation premium that is disconnected from current revenue generation and relies entirely on the successful clinical validation of the GEAR platform rather than existing commercial fundamentals.

The elevated P/S multiple suggests that investors are pricing the company as a high-growth biotech entity, yet the lack of a forward P/E or meaningful EBITDA indicates that this valuation is purely speculative. Analysts should note that such multiples are highly sensitive to clinical trial news, and any delay in the CD38-GEAR-NK program could lead to a rapid compression of this valuation.

Capital Erosion Through Persistent Losses

Based on reported financial figures, Coeptis has consistently generated negative returns on invested capital, with ROIC plummeting to -63.2% in 2023Q4, indicating that the company is currently destroying shareholder value as it attempts to fund its early-stage research and development pipeline through external capital.

The persistent negative ROIC trend highlights the structural difficulty of achieving efficiency in a pre-commercial biotech model where R&D costs are inelastic. Investors should monitor whether the company can eventually pivot toward a partnership-based model that reduces the burden on its own capital base, as current trends suggest a continued reliance on dilutive financing.

Working Capital Volatility and Inefficiency

As reported in financial statements, the company's cash conversion cycle remains highly erratic, with days payable outstanding reaching as high as 2382 in 2025Q1, suggesting that Coeptis is managing its liquidity by significantly delaying payments to vendors rather than through operational efficiency or optimized working capital management.

The extreme fluctuations in DPO indicate that the company's cash management is reactive to its limited liquidity position rather than strategic. This reliance on extended payment terms may pose operational risks if suppliers tighten credit, potentially jeopardizing the continuity of clinical trial activities.

Precarious Runway Threatens Operational Continuity

Based on the provided quarterly data, the current ratio has swung from a low of 0.23 in 2024Q4 to 3.25 in 2026Q1, which indicates that the company's ability to meet short-term obligations is entirely dependent on the timing of capital raises rather than stable internal cash generation.

The volatility in the current ratio underscores the company's vulnerability to liquidity shocks. Without a consistent source of revenue, the company remains in a state of perpetual capital dependency, which warrants close investigation by analysts regarding the timing and terms of future equity or debt issuances.

Misapplication of Traditional Valuation Metrics

Investors frequently misapply the price-to-earnings ratio to Coeptis, which obscures the company's true financial health by focusing on accounting losses that are expected in a pre-revenue biotech firm, rather than evaluating the cash runway and the probability-weighted value of its clinical pipeline assets.

Using P/E or EV/EBITDA for a company with negative margins and no commercial product is fundamentally flawed, as these metrics fail to capture the value of the GEAR platform's intellectual property. A more appropriate approach would involve a risk-adjusted net present value analysis of the clinical pipeline, which accounts for the high probability of failure inherent in early-stage biotechnology.

Download Financial Ratios Data

Includes 30+ ratios · 9 years · Updated daily

Consensus & Technical Research Suite
Open ZSQR Terminal

ZSQR Chart Terminal

WASM

Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.

Launch Terminal

Live Breakouts Feed

LIVE

High-probability breakout stocks crossing their pivot across 5 pattern engines.

Explore Setups

Intrinsic Valuation

DCF models, multiple analysis, and analyst estimates.

Check Valuation

Historical Returns

10-year return with dividends reinvested.

Calculate

Peer Comparison

Compare growth, multiples, and margins vs sector.

Compare

ZSQR — Frequently Asked Questions

Quick answers to the most common questions about buying ZSQR stock.

What is Z Squared Inc.'s P/E ratio?

Z Squared Inc.'s current P/E ratio is -5.0x. This places it at the 50th percentile of its historical range.

What is Z Squared Inc.'s ROE?

Z Squared Inc.'s return on equity (ROE) is -100.5%. The historical average is -147.9%.

Is ZSQR stock overvalued?

Based on historical data, Z Squared Inc. is trading at a P/E of -5.0x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.

What are Z Squared Inc.'s profit margins?

Z Squared Inc. has -207.8% gross margin and -956.9% operating margin.